BioSpace News Archive

XyloCor Therapeutics reported positive topline results Thursday from Phase II of the Phase I/II trial of its gene therapy for refractory angina.

Celularity announced Thursday it was conducting a strategic review and warned its workforce to brace for potential layoffs.

The FDA approved Merck’s Keytruda for the treatment of stage IB, II or IIIA non-small cell lung cancer after resection or platinum-based chemotherapy.

Sen. Elizabeth Warren (D-MA) voiced concerns to the FTC regarding the prospective acquisitions of Horizon Pharmaceuticals and Opiant Pharmaceuticals by Amgen and Indivior.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”) today announced it has entered into a definitive agreement with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of its common stock (the “Shares”), pursuant to a registered direct offering (the “Registered Direct Offering”), and warrants to purchase up to 4,796,206 Shares (the “Warrants”), in a concurrent private placement (the “Private Placement”).

Infinity Neuro announced today that its Inspira™ aspiration catheters received CE Mark approval and are now commercially available in Europe.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) announced today that CARTITUDE-4, the Phase 3 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint of showing a statistically significant improvement in progression-free survival (PFS) compared to standard therapy at the study’s first pre-specified interim analysis.

Precision Optics Corporation, Inc. announced Dr. Joe Forkey, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reported that its Phase 2 clinical trial protocol has received study level approval from a central institutional review board (“IRB”).

Prenatal exposure to perfluorononanoic acid (PFNA), a chemical sometimes found in food or drinking water, is associated with autism-related traits in children, according to a new study funded by the Environmental influences on Child Health Outcomes Program (ECHO) at the National Institutes of Health.